Navigation Links
Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research

SOUTH SAN FRANCISCO, Calif., April 13, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in Los Angeles, California.

Data being presented in a poster session will focus on non-clinical data on SNS-032, a highly selective and potent inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9 that is currently in a Phase 1 clinical trial for B-cell malignancies. Abstract #1815: "SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226" will be presented on Monday, April 16, 2007 from 8:00 a.m. to 12:00 p.m. in poster section 7, board #1.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute myeloid leukemia for its lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitor compound, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314 is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of targeted cancer therapeutics. Sunes
'"/>




Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:11/28/2014)... , Nov. 28, 2014 Alimera Sciences, ... pharmaceutical company that specializes in the research, development ... into a Securities Purchase Agreement with Deerfield Management ... which Alimera will issue shares of preferred stock ... approximately $50.0 million upon the satisfaction of certain ...
(Date:11/27/2014)... CORK, Ireland , November 27, 2014 ... first Investigational New Drug (IND) Application with the U.S. ... milestone in Hovione,s strategy of developing improved drug delivery ... submitted for minocycline gel, a novel formulation using a ... topically one of the most widely prescribed oral antibiotics ...
(Date:11/26/2014)... -- Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it has ... million at a price of $0.30 per unit. The ... Each unit consists of one common share and one ... whole warrant entitles the holder to acquire one common ... of five years from closing.  Roth ...
Breaking Medicine Technology:Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Hovione Files its First Investigational New Drug Application With the FDA 2Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3
... Therapeutics (Nasdaq: NKTR ) today reported its financial ... 2010. Cash, cash equivalents, and short-term investments ... at December 31, 2010 does not include proceeds of $220.4 ... in January 2011.   Revenue for the fourth ...
... 2011 OncoMed Pharmaceuticals, Inc., a company developing novel ... publication of preclinical data demonstrating that its lead candidate, ... frequency when administered alone or in combination with chemotherapy ... mutations.  This study was published in the March 1, ...
Cached Medicine Technology:Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 7OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 2OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 3OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 4OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 5
(Date:11/28/2014)... Melbourne, Australia (PRWEB) November 28, 2014 ... has undergone healthy growth over the past five ... population's increasing acceptance of therapies that are either ... conventional treatments. According to IBISWorld industry analyst David ... the ageing population and growing private health insurance ...
(Date:11/28/2014)... Kramer HealthDay Reporter , THURSDAY, ... the kitchen, through cooking classes or at home, may make ... recent review. Cooking programs and classes for children seem ... the new research. And, although the review didn,t look at ... programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... November 28, 2014 Mabel’s Labels ... kids lose® and an award-winning company established by four ... Cynthia Esp, and Tricia Mumby have been honored with ... recognized with the PROFIT Award for Excellence in Entrepreneurship. ... Esp, and Tricia Mumby) accepted the award on behalf ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Patten Pecans, ... locally grown. With those passions driving them, they've added ... Grown. Having tried other pecans oils, they've found this ... Georgia to be exceptionally flavorful, retaining the buttery pecan ... same nutritional benefits found in pecans nuts ...
(Date:11/28/2014)... Brentwood, TN (PRWEB) November 28, 2014 ... in Tennessee for the first time. PAI Medical Group ... M.D. will be performing a robotic hair transplant procedure ... at 9:00 A.M. , The first in Tennessee and ... PAI Medical Group now offers ARTAS robotic hair transplantation. ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2
... from more emotional and behavioral difficulties when compared to ... the most when a parent is deployed overseas, according ... that having a parent deployed for a longer period ... struggled with emotional problems were important factors associated with ...
... , NEW ORLEANS and SUNNYVALE, Calif., Dec. ... interim results from a Phase I/II study showing safety and ... (NHL) treated with its HDAC inhibitor PCI-24781 as a single ... Annual Meeting being held in New Orleans, LA (Abstract # ...
... growth factor, researchers say , SUNDAY, Dec. 6 (HealthDay ... main tumor to other parts of the body is controlled ... a promising target for new drugs to prevent metastatic breast ... TGFb (transforming growth factor beta) regulates normal cell growth and ...
... NEW ORLEANS, Dec. 6 Sickle cell disease, a condition ... of the most common genetic blood disorders affecting millions of ... presented today at the 51st Annual Meeting of the American ... that the H1N1 pandemic presents for children with this blood ...
... ... Greater VA Healthcare System in West Los Angeles, will once again create a holiday party. ... and their families. , ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the community, in cooperation ...
... 5 , What: Cuts for a Cause ... fight against cancer and other terminal illnesses affecting children. All proceeds ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... Falls Church for all guests. Hoa Lai, a DJ known for ...
Cached Medicine News:Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
... fixation device offers superior fixation strength ... firmly reattaches soft tissue to the ... is indicated for the fixation of ... bone. The implant is composed of ...
... simple to use system can be used ... and is pre-packaged on a sterile disposable ... a simple and reproducible insertion of the ... Sliding (I.S.S.™) Eyelet Design allows for the ...
... is the smallest, strongest anchor on ... placement into even the smallest bones. ... or 4-0 ETHIBOND EXCEL suture with ... swaged needles. The kit includes a ...
Medicine Products: